Mello EL, Pena NG, Souza VA, Silva CM, Ribeiro LN, Albuquerque RF, et al. Incidence of oral manifestations in hematological malignancy patients undergoing chemotherapy: prospective cohort study. Med Oral Patol Oral Cir Bucal. 2025 Jan 1;30 (1):e17-23.


doi:10.4317/medoral.26652

https://dx.doi.org/doi:10.4317/medoral.26652


1. Yong CW, Robinson A, Hong C. Dental Evaluation Prior to Cancer Therapy. Front Oral Health. 2022;3:876941.

https://doi.org/10.3389/froh.2022.876941

PMid:35510226 PMCid:PMC9058061

2. Tseng YD, Ng AK. Hematologic Malignancies. Hematol Oncol Clin North Am. 2020;34:127-42.

https://doi.org/10.1016/j.hoc.2019.08.020

PMid:31739939 

3. Silva TD, Ferreira CB, Leite GB, de Menezes Pontes JR, Antunes HS. Oral manifestations of lymphoma: a systematic review. Ecancermedicalscience. 2016;10:665.

https://doi.org/10.3332/ecancer.2016.665

PMid:27594910 PMCid:PMC4990057

4. Jena S, Hasan S, Panigrahi R, Das P, Mishra N, Saeed S. Chemotherapy-associated oral complications in a south Indian population: a cross-sectional study. J Med Life. 2022;15:470-8.

https://doi.org/10.25122/jml-2021-0342

PMid:35646189 PMCid:PMC9126462

5. Tang L, Huang Z, Mei H, Hu Y. Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduct Target Ther. 2023;8:306.

https://doi.org/10.1038/s41392-023-01521-5

PMid:37591844 PMCid:PMC10435569

6. Curra M, Soares Junior LAV, Martins MD, Santos PS da S. Chemotherapy protocols and incidence of oral mucositis. An integrative review. Einstein. 2018;16:eRW4007.

https://doi.org/10.1590/s1679-45082018rw4007

PMid:29694618 PMCid:PMC5968807

7. Ramírez-Amador V, Esquivel-Pedraza L, Mohar A, Reynoso-Gómez E, Volkow-Fernández P, Guarner J, et al. Chemotherapy-associated oral mucosal lesions in patients with leukaemia or lymphoma. Eur J Cancer B Oral Oncol. 1996;32B:322-7.

https://doi.org/10.1016/0964-1955(96)00020-6

PMid:8944835 

8. Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52-79.

https://doi.org/10.1016/j.ejpb.2015.03.018

PMid:25813885 

9. Karthaus M, Rosenthal C, Huebner G, Paul H, Elser C, Hertenstein B, et al. Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial. Bone Marrow Transplant. 1998;22:781-5.

https://doi.org/10.1038/sj.bmt.1701434

PMid:9827976 

10. Chen YK, Hou HA, Chow JM, Chen YC, Hsueh PR, Tien HF. The impact of oral herpes simplex virus infection and candidiasis on chemotherapy-induced oral mucositis among patients with hematological malignancies. Eur J Clin Microbiol Infect Dis. 2011;30:753-9.

https://doi.org/10.1007/s10096-010-1148-z

PMid:21225303 

11. Keykhaei M, Masinaei M, Mohammadi E, Azadnajafabad S, Rezaei N, Saeedi Moghaddam S, et al. A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990-2017. Exp Hematol Oncol. 2021;10:11.

https://doi.org/10.1186/s40164-021-00198-2

PMid:33557940 PMCid:PMC7869509

12. Hiromi N, Kouji O, Yuri K, Hideo S, Taiji O, Yukio Y, et al. Periodontal inflamed surface area in oral cavity associated with febrile neutropenia in patients with hematologic malignancy undergoing chemotherapy. Sci Rep. 2022;12:2483.

https://doi.org/10.1038/s41598-022-06485-0

PMid:35169215 PMCid:PMC8847642

13. Zhang N, Wu J, Wang Q, Liang Y, Li X, Chen G, et al. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J. 2023;13:82.

https://doi.org/10.1038/s41408-023-00853-3

PMid:37193689 PMCid:PMC10188596

14. Horesh N, Horowitz NA. Does gender matter in non-hodgkin lymphoma? Differences in epidemiology, clinical behavior, and therapy. Rambam Maimonides Med J. 2014;5:e0038.

https://doi.org/10.5041/RMMJ.10172

PMid:25386354 PMCid:PMC4222427

15. Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of Non-Hodgkin's Lymphoma. Med Sci (Basel). 2021;9:5.

https://doi.org/10.3390/medsci9010005

PMid:33573146 PMCid:PMC7930980

16. García-Chías B, Figuero E, Castelo-Fernández B, Cebrián-Carretero JL, Cerero-Lapiedra R. Prevalence of oral side effects of chemotherapy and its relationship with periodontal risk: a cross sectional study. Support Care Cancer. 2019;27:3479-90.

https://doi.org/10.1007/s00520-019-4650-6

PMid:30675665 

17. Jensen SB, Pedersen AM, Vissink A, Andersen E, Brown CG, Davies AN, Dutilh J, et al. Salivary Gland Hypofunction/Xerostomia Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO). A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer. 2010;18:1039-60.

https://doi.org/10.1007/s00520-010-0827-8

PMid:20237805 

18. Ortiz F, Acuña-Castroviejo D, Doerrier C, Dayoub JC, López LC, Venegas C, et al. Melatonin blunts the mitochondrial/NLRP3 connection and protects against radiation-induced oral mucositis. J Pineal Res. 2015;58:34-49.

https://doi.org/10.1111/jpi.12191

PMid:25388914 

19. Miller MM, Donald DV, Hagemann TM. Prevention and treatment of oral mucositis in children with cancer. J Pediatr Pharmacol Ther. 2012;17:340-50.

https://doi.org/10.5863/1551-6776-17.4.340

PMid:23413048 PMCid:PMC3567887

20. Marín-Conde F, Castellanos-Cosano L, Pachón-Ibañez J, Serrera-Figallo MA, Gutiérrez-Pérez JL, Torres-Lagares D. Photobiomodulation with low-level laser therapy reduces oral mucositis caused by head and neck radio-chemotherapy: prospective randomized controlled trial. Int J Oral Maxillofac Surg. 2019;48:917-23.

https://doi.org/10.1016/j.ijom.2018.12.006

PMid:30591391 

21. Anschau F, Webster J, Capra MEZ, de Azeredo da Silva ALF, Stein AT. Efficacy of low-level laser for treatment of cancer oral mucositis: a systematic review and meta-analysis. Lasers Med Sci. 2019;34:1053-62.

https://doi.org/10.1007/s10103-019-02722-7

PMid:30729351 

22. Giudice A, Liborio F, Averta F, Barone S, Fortunato L. Oral Lichenoid Reaction: An Uncommon Side Effect of Rituximab. Case Rep Dent. 2019;2019:3154856.

https://doi.org/10.1155/2019/3154856

PMid:31781409 PMCid:PMC6875254

23. Kuten-Shorrer M, Hochberg EP, Woo SB. Lichenoid mucosal reaction to rituximab. Oncologist. 2014;19:e12-3.

https://doi.org/10.1634/theoncologist.2014-0169

PMid:25170011 PMCid:PMC4200996

24. Coelho AA, Carvalho RR, Muniz AL, Crispim AA, Meneses AM, Silva CWD, et al. CD20 + cells blockage by rituximab delays wound healing in oral traumatic ulcers in rats. Arch Oral Biol. 2024;157:105844.

https://doi.org/10.1016/j.archoralbio.2023.105844

PMid:37950958 

25. Abromowitch M, Sposto R, Perkins S, Zwick D, Siegel S, Finlay J, et al. Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children's Oncology Group. Br J Haematol. 2008;143:261-7.

https://doi.org/10.1111/j.1365-2141.2008.07320.x

PMid:18759768 PMCid:PMC3057023